statins, one of the leading lipid-lowering therapies, actually
achieve healthy levels of LDL-C; and
WHEREAS, The total direct and indirect cost of ASCVD in the
United States was $555 billion in 2016 and is projected to climb
to $1.1 trillion by 2035 according to the American Heart
Association; and
WHEREAS, In Pennsylvania, 931,400 adults have been told by a
health professional that they had angina, a stroke, a heart
attack or coronary heart disease, which are some of the
manifestations of ASCVD; and
WHEREAS, In Pennsylvania, 17,653 people had ASCVD as an
underlying cause of death; and
WHEREAS, In Pennsylvania, 456,300 adults reported
experiencing a heart attack in their lifetime, and 382,400
adults reported experiencing a stroke in their lifetime; and
WHEREAS, Pennsylvania spends an estimated $5.5 billion on
direct medical expenses for ASCVD care each year; therefore be
it
RESOLVED, That the Senate of the Commonwealth of Pennsylvania
designate the month of February 2023 as "Atherosclerotic
Cardiovascular Disease Month" in Pennsylvania; and be it further
RESOLVED, That the Senate of the Commonwealth of Pennsylvania
urge Commonwealth agencies to expand comprehensive
cardiovascular screening programs to allow for earlier
identification of patients at risk of cardiovascular events; and
be it further
RESOLVED, That the Senate of the Commonwealth of Pennsylvania
urge Commonwealth agencies to explore ways to collaborate with
Federal public and private national agencies and organizations
to establish or expand comprehensive cardiovascular screening
20230SR0056PN0471 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30